You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

454 Results
Statistical Reports
Statistical Reports
Drug
Other Name(s): Tepadina®
Jan 2023
Regimen
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer
Sep 2023
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Nov 2024
Guidelines and Advice
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
Exceptional Access Program
    trifluridine / tipiracil - In combination with bevacizumab for treatment of metastatic colorectal cancer, according to clinical criteria
New Drug Funding Program
    Bevacizumab (Biosimilar) - In Combination with Trifluridine and Tipiracil for Previously Treated Metastatic Colorectal Cancer
Nov 2024
Drug
Other Name(s): Kimmtrak®
Apr 2024
Guidelines and Advice
Regimen
Intent: Curative, Palliative
Funding:
New Drug Funding Program
    Azacitidine in combination with Venetoclax (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Exceptional Access Program
    venetoclax - Venetoclax in combination with azacitidine - Previously untreated acute myeloid leukemia
Apr 2024
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative
Apr 2024

Pages